Porcine Vaccine Market Report 2025

The porcine vaccine market size has grown strongly in recent years. It will grow from $1.89 billion in 2024 to $2.06 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to disease outbreaks and control measures, global increase in pork consumption, intensification of pig farming, government initiatives for disease control, awareness and education programs.

The porcine vaccine market size is expected to see strong growth in the next few years. It will grow to $2.96 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to global expansion of pig farming, rising disease challenges, stringent regulations and compliance, technological advancements in vaccine development, global trade and disease risk mitigation. Major trends in the forecast period include customization of vaccines for regional challenges, integration of biotechnology in vaccine development, rising concerns about zoonotic diseases, application of genomic approaches in vaccine design, growing investments in research and development.

The increasing prevalence of swine diseases is expected to drive the growth of the porcine vaccine market. Swine influenza (swine flu) is a respiratory illness commonly affecting pigs, often caused by the type A influenza virus, which can lead to frequent influenza outbreaks in pig populations. Porcine vaccines, when administered to pigs, stimulate their immune systems to recognize and respond to pathogenic agents by inducing an immunogenic reaction. This immune response helps the swine fight off pathogens and prevents disease through an anamnestic reaction when exposed to the same pathogen again. For example, in September 2024, the Government of the United Kingdom reported that an outbreak of African swine fever (ASF) could have severe consequences for the UK’s £8 billion pig industry and its £600 million annual pork export sector, with potential financial impacts estimated between £10 million and £100 million. Therefore, the rising incidence of swine diseases is fueling growth in the porcine vaccine market.

The increasing consumption of pork is expected to contribute to the growth of the porcine vaccine market. As the global population grows, there is a rising demand for protein, leading to an increase in pork consumption. To meet this demand efficiently, pig farming has become more intensive, making vaccinations essential for maintaining the health and productivity of pig herds. For instance, in March 2022, Pig333 reported that pork consumption in China was approximately 61, 52, and 37 kg per inhabitant. The projections indicate a 4.1% growth in consumption in China by 2022, reaching almost 52 kg per inhabitant. This upward trend in pork consumption underscores the importance of porcine vaccines in supporting the health and sustainability of pig farming, thereby driving the growth of the porcine vaccine market.

Leading companies in the porcine vaccine market are forming strategic partnerships to boost research and development and enhance their competitiveness in the fast-changing animal health sector. One such collaboration leverages The Vaccine Group’s (TVG) vaccine technology expertise and The Pirbright Institute’s knowledge of African swine fever (ASF) research to advance the vaccine development process and create innovative solutions for swine health. For instance, in May 2024, The Pirbright Institute, a UK-based research organization, partnered with TVG, a UK-based company, to develop an ASF vaccine using bovine herpesvirus 4 (BoHV-4) as a platform. This approach incorporates the latest advancements in ASF vaccine research and pig immunology to improve vaccine efficacy. The initiative is funded by the U.K. Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

The noteworthy development involves major companies in the porcine vaccine market introducing innovative products such as the 3-in-one swine vaccine, offering enhanced protection against various diseases. Merck Animal Health, a US-based pharmaceutical company, launched Circumvent CML in June 2023. This three-in-one vaccine controls Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. The product provides convenience and assurance to producers and caregivers, simplifying the vaccination process and reducing the number of injections for younger pigs. Built on a foundation of proven adjuvant systems and antigens, Circumvent CML signifies a novel approach in swine vaccination.

In July 2024, Merck Animal Health Inc., a US-based company, acquired Elanco Animal Health Inc. for an undisclosed amount. Through this acquisition, Merck Animal Health aims to broaden its portfolio by integrating Elanco's expertise in porcine vaccines. Elanco Animal Health, also a US-based company, specializes in providing porcine vaccines, supporting the health and immunity of swine populations.

Major companies operating in the porcine vaccine market include Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Arko Laboratories Limited, Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., Ringpu Bio-Pharmacy Co Ltd., IDT Biologika GmbH, Bimeda Holdings PLC, Jinyu Bio-Technology Co Ltd., Biogénesis Bagó, Pharmaq AS, Veterquimica S.A., Kyoto Biken Laboratories Inc., Dopharma Research B.V., Agrovet Market Animal Health Ltd., Innovad SA, PBS Animal Health, Merial Animal Health, Aptimmune Biologics Inc., Syntex SA de CV, Zoovet S.A., Shenzhen Weierkang Xiang Animal Pharm Co Ltd., Wuhan Keqian Biology Co Ltd., Anicon Labor GmbH.

North America is the largest region in the porcine vaccine market in 2024. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the porcine vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Porcine vaccines are medical and pharmaceutical treatments designed to enhance the health of pigs by protecting them from various bacteria, viruses, and infections. These vaccines aim to increase the effectiveness of safeguarding pigs from harmful diseases while also improving the production of high-quality meat for human consumption.

In the realm of porcine vaccines, major technologies include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. Inactivated vaccines, for instance, are made from killed or inactivated viruses or bacteria and stimulate an immune response to protect pigs against natural infections. These vaccines are employed to address various diseases such as diarrhea, swine influenza, arthritis, bordatella rhinitis, porcine reproductive and respiratory virus (PRRSV), porcine circovirus-associated disease (PCVAD), and others, commonly utilized in hospitals and pig production farms.

The porcine vaccines market research report is one of a series of new reports that provides porcine vaccines market statistics, including porcine vaccines industry global market size, regional shares, competitors with a porcine vaccines market share, detailed porcine vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the porcine vaccines industry. This porcine vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The porcine vaccines market consists of sales of antibacterial vaccines and antiviral vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.